GS-7977: A promising nucleotide analog NS5B polymerase inhibitor of HCV

Future Virology

Volumn 7, Issue 6, 2012, Pages 537-546

  Martel Laferrière, Valérie ^a   Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

GS 7977; GS 9851; hepatitis C; NS5B polymerase inhibitor; nucleotide analog; PSI 7977

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; BOCEPREVIR; GAMMA INTERFERON; GS 0938; GS 7977; MERICITABINE; METHADONE; MOXIFLOXACIN; N (2' DEOXY 2' FLUORO 2' METHYL P PHENYL 5' URIDYLYL)ALANINE ISOPROPYL ESTER; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; PLACEBO; PRODRUG; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VITRELIS;

ANEMIA; ANXIETY; CHILL; CLINICAL TRIAL (TOPIC); DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VIRUS GENOME;

HEPATITIS C VIRUS;

EID: 84862003649     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.34     Document Type: Review

References (36)

1. Armstrong GL, Wasley A, Simard EP, McQuillan G, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144(10), 705-714 (2006).
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4), 1433-1444 (2011).
3. Poordad F, McCone J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195-1206 (2011).
4. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405-2416 (2011).
5. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364(25), 2417-2428 (2011).
6. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1207-1217 (2011).
7. Nainan OV, Alter MJ, Kruszon-Moran D et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131(2), 478-484 (2006).
8. Khattab MA, Ferenci P, Hadziyannis SJ et al. Management of hepatitis C genotype 4: recommendations of an international expert panel. J. Hepatol. 54, 1250-1262 (2011).
9. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin. Infect. Dis. doi:10.1093/cid/cir774 (2011) (Epub ahead of print).
10. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokines storm. Gut 60, 1284-1293 (2011). Extensive review of IFN-l and IL28B polymorphism.
11. Vachon ML, Dieterich DT. The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin. Liver Dis. 31, 399-409 (2011).
12. Sofia MJ, Bao D, Chang W et al. Discovery of a β-D-20-deoxy-20-r- fluoro-20-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53(19), 7202-7218 (2010).
13. Lam AM, Murakami E, Espiritu C, Steuer HM et al. PSI-7851, a pronucleotide of β-D-2′-deoxy-2′-fluoro-2′-C- methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob. Agents Chemother. 54(8), 3187-3196 (2010).
14. Legrand-Abravanel F, Nicot F, Izopet J. New NS5B polymerase inhibitors for hepatitis C. Exp. Opin. 19(8), 963-975 (2010). Review of NS5B nucleos(t)ide and non-nucleoside inhibitors published in 2010 and before. Includes a comparison of the differences between the two classes.
15. Furman PA, Bao D, Chang W et al. β-D-2′-deoxy-2′-fluoro- 2′-C-methyluridine phosphoramidates are potent and selective inhibitors of HCV RNA replication. Presented at: 15th International Symposium on Hepatitis C Virus and Related Viruses. San Antonio, TX, USA, 5-9 October 2008.
16. Furman PA, Wang P, Niu C. PSI-7851: a novel liver-targeting nucleotide prodrug for the treatment of hepatitis C. Presented at: The 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, USA, 31 October-4 November 2008.
17. Lawitz E, Lalezari JP, Hassanein T et al. PROTON: PSI-7977 & peg/RBV in treatment-naive patients with HCV GT1: sustained virologic response. Presented at: The 62th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, USA, 5-8 November 2011.
18. Rodriguez-Torres M, Lawitz E, Flach S et al. Antiviral activity, pharmacokinetics, safety, and tolerability of PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following single and 3 day multiple ascending oral doses in healthy volunteers and patients with chronic HCV infection. Presented at: The 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA, 30 October-3 November 2009.
19. Lawitz E, Lalezari JP, Rodriguez-Torres M et al. Clinical synergy of an anti-HCV nucleotide analog with SOC: viral kinetics of PSI-7977 with SOC. Presented at: The 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA, 30 October-2 November 2010.
20. Denning JM, Cornpropst MT, Clemons D et al. Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone PK and PD. Presented at: The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, USA, 5-8 November 2011.
21. Cornpropst MT, Denning JM, Clemons D et al. PSI-7977 has no effect on QTcF intervals at therapeutic or supratherapeutic doses. Presented at: The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, USA, 5-8 November 2011.
22. Lawitz E, Rodriguez-Torres M, Denning J et al. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA > LOD at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). Presented at: European Association for the Study of the Liver (EASL). The International Liver Congress 2011. Berlin, Germany, 30 March-2 April 2011.
23. Lawitz E, Lalezari J, Rodriguez-Torres M, Kowdley KV et al. High rapid virologic response (RVR) with PSI-7977 daily dosing plus PEG-IFN/RBV in a 28-day Phase 2a trial. Presented at: The 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA, 30 October-2 November 2010.
24. McHutchison JG, Goldstein DB, Shianna K et al. IL28B SNP geographical distribution and antiviral responses in a 28-day Phase 2a trial of PSI-7977 daily dosing plus PEG-IFN/RBV. Presented at: The 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA, 30 October-2 November 2010.
25. Lalezari J, Lawitz E, Rodriguez-Torres M et al. PROTON study: PSI-7977 QD with PEG/RBV: 12-week safety, RVR, cEVR, & SVR12 in treatment-naive patients with HCV GT2 or GT3. Presented at: European Association for the Study of the Liver (EASL). The International Liver Congress 2011. Berlin, Germany, 30 March-2 April 2011.
26. Lok A, Gardiner D, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366(3), 216-224 (2012).
27. Gane EJ, Stedman CA, Hyland RH et al. PSI-treatment-naive 7977: ELECTRON interferon is not required for sustained virologic response in treatment naive patients with HCV GT2 or GT3. Presented at: The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, CA, USA, 5-8 November 2011.
28. Gane E, Stedman C, Anderson J et al. PSI-7977 + ribavirin in HCV genotype 1 null responders: results from the ELECTRON trial. Presented at: 19th Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA, USA, 5-8 March 2012.
29. Hassanein T, Nelson DR, Lawitz E et al. PSI-7977 with PEG/RBV elicits rapid declines in HCV RNA in patients with HCV GT-4 and GT-6. Presented at: HepDart 2011. Kauai, HI, USA, 4-8 December 2011.
30. Symonds WT, Denning JM, Albanis E et al. Pharmacokinetics, safety, and tolerability of PSI-352938, a novel nucleotide polymerase inhibitor for HCV, following single ascending oral doses in healthy subjects. Presented at: The 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA, 30 October-2 November 2010.
31. Nelson DR, Lalezari J, Lawitz E et al. PSI-7977 QD plus PEG/RBV in HCV GT1: 98% rapid virologic response, complete early virologic response: the PROTON Study. Presented at: European Association for the Study of the Liver (EASL). The International Liver Congress 2011. Berlin, Germany, 30 March-2 April 2011.
32. Centers for Disease Control and Prevention: Viral Heaptitis Surveillance - United States, 2009. www.cdc.gov/hepatitis/Statistic/2009Surveillance/index. htm
33. Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C. http://clinicaltrials.gov/ct2/show/NCT01447394
34. Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE). http://clinicaltrials.gov/ct2/show/ NCT01309932
35. Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (EMERGE). http://clinicaltrials.gov/ct2/show/ NCT01001754
36. Pharmasset Inc. Press Releases. http://investor.pharmasset.com/releases. cfm